Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0020672 (
hypothermia
)
17,327
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Background:
Night sweats
significantly impact the quality of life for cancer patients and are often resistant to treatment. Cannabinoids have been shown to modulate cytokine activity and produce
hypothermia
in animal models, suggesting that they may be a promising candidate for palliation of
night sweats
in patients with oncologic disease.
Objective:
Assess efficacy of the oral cannabinoid, dronabinol, for palliation of
night sweats
in cancer patients.
Design:
A retrospective record search identified five cancer patients who had tried oral dronabinol for palliation of their
night sweats
between 2013 and 2016 and subjectively reported on its efficacy.
Setting/Subjects:
A convenience sample of five patients from the outpatient consultative palliative medicine program at Stanford Medical Center was chosen from a search of past records. Patients were included if they had a cancer diagnosis and complained of
night sweats
that subjectively interfered with their quality of life. All agreed to try oral dronabinol for palliation of their
night sweats
.
Measurements:
Patients self-reported the effect of oral synthetic dronabinol on their
night sweats
.
Results:
Treatment of five patients with advanced cancer with synthetic orally administered dronabinol resulted in the successful management of persistent symptomatic paraneoplastic
night sweats
.
Conclusion:
Dronabinol and/or medicinal cannabis are promising therapies for palliation of
night sweats
in cancer patients.
...
PMID:Dronabinol for the Treatment of Paraneoplastic Night Sweats in Cancer Patients: A Report of Five Cases. 3075 37
